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Whole genome characterization of the mechanisms of daptomycin resistance in
clinical and laboratory derived isolates of Staphylococcus aureus
Abstract
Background
Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the
genetic evolution to daptomycin resistance in S. aureus.
Methods
Whole genome sequencing was performed on a unique collection of isogenic, clinical (21 strains) and
laboratory (12 strains) derived strains that had been exposed to daptomycin and developed daptomycinnonsusceptibility. Electron microscopy (EM) and lipid membrane studies were performed on selected
isolates.
Results
On average, six coding region mutations were observed across the genome in the clinical daptomycin
exposed strains, whereas only two mutations on average were seen in the laboratory exposed pairs. All
daptomycin-nonsusceptible strains had a mutation in a phospholipid biosynthesis gene. This included
mutations in the previously described mprF gene, but also in other phospholipid biosynthesis genes,
including cardiolipin synthase (cls2) and CDP-diacylglycerol-glycerol-3-phosphate
3-phosphatidyltransferase (pgsA). EM and lipid membrane composition analyses on two clinical pairs
showed that the daptomycin-nonsusceptible strains had a thicker cell wall and an increase in membrane
lysyl-phosphatidylglycerol.
Conclusion
Point mutations in genes coding for membrane phospholipids are associated with the development of
reduced susceptibility to daptomycin in S. aureus. Mutations in cls2 and pgsA appear to be new genetic
mechanisms affecting daptomycin susceptibility in S. aureus.
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Abstract
Background
Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to
characterize the genetic evolution to daptomycin resistance in S. aureus.

Methods
Whole genome sequencing was performed on a unique collection of isogenic, clinical (21 strains)
and laboratory (12 strains) derived strains that had been exposed to daptomycin and developed
daptomycin-nonsusceptibility. Electron microscopy (EM) and lipid membrane studies were
performed on selected isolates.

Results
On average, six coding region mutations were observed across the genome in the clinical
daptomycin exposed strains, whereas only two mutations on average were seen in the
laboratory exposed pairs. All daptomycin-nonsusceptible strains had a mutation in a
phospholipid biosynthesis gene. This included mutations in the previously described mprF gene,
but also in other phospholipid biosynthesis genes, including cardiolipin synthase (cls2) and CDPdiacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase (pgsA). EM and lipid membrane
composition analyses on two clinical pairs showed that the daptomycin-nonsusceptible strains
had a thicker cell wall and an increase in membrane lysyl-phosphatidylglycerol.

Conclusion
Point mutations in genes coding for membrane phospholipids are associated with the
development of reduced susceptibility to daptomycin in S. aureus. Mutations in cls2 and pgsA
appear to be new genetic mechanisms affecting daptomycin susceptibility in S. aureus.
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I NTRODUCTION
Staphylococcus aureus is one of the most significant human bacterial pathogens, causing immense
morbidity and mortality in hospitalised patients, as well as in the community. It causes a diverse
range of clinical disease, with mortality from infection reported as high as 35% [1]. Compounding
this severity of disease is the constant adaptation of the bacteria to antibiotic pressure, with the
emergence of resistance in S. aureus now being one of the most important public health problems
in the developed world. As a consequence of this resistance, reliance on ‘last-line’ antistaphylococcal agents such as vancomycin, linezolid, and daptomycin has increased dramatically
over recent years, and unfortunately, reduced susceptibility to these agents has also been described
[2], [3].

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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Daptomycin is a cyclic lipopeptide antibiotic that has recently been FDA approved for the treatment
of complicated skin and soft tissue infections, and S. aureus bacteremia with or without right-sided
endocarditis [2]. Understanding the mechanism of action of daptomycin has remained challenging,
but current evidence indicates that it interacts with the bacterial cytoplasmic membrane in a
calcium-dependent manner, leading to potassium efflux and membrane depolarisation, with
subsequent cell death [4], [5]. Using model membranes, it has been shown that negatively charged
lipids in the presence of calcium allow daptomycin to insert and perturb bilayer membranes [4].
Importantly, the majority of S. aureus membrane lipids are comprised of negatively charged
phospholipids: phosphatidylglycerol (PG) and cardiolipin [4].
Therapeutic failures with daptomycin for infections due to S. aureus have now been reported, with
many of these being associated with the evolution of reduced susceptibility to daptomycin in the
setting of deep-seated and poorly controlled infection [2], [6], [7], [8]. The mechanisms of
daptomycin resistance in S. aureus have focused on the role of the staphylococcal membrane
protein, MprF. MprF is a bifunctional protein that mediates both the lysinylation of PG and its
translocation to the outer leaflet of the membrane [9]. Point mutations within MprF have been
described in S. aureus strains with reduced susceptibility to daptomycin, and such mutations appear
to cause a gain-in-function, hypothesized to result in accelerated membrane translocation of LysylPG (L-PG), thereby resulting in a reduced net-negative membrane charge that may electrostatically
repel calcium-complexed daptomycin [10]. Other mutations that have been reported include
mutations in walK (previously yycG), which encodes a sensor histidine kinase that regulates cell
wall metabolism and virulence, and a point mutation in each of rpoB and rpoC, encoding subunits of
RNA polymerase [11]. Furthermore, increased expression of the dltABCD operon, which is
responsible for D-alanylating wall teichoic acids and contributes to the net-positive surface charge,
has been shown to be associated with reduced susceptibility to daptomycin [10]. Thus far, the
study of the genetic mechanisms of daptomycin resistance have been limited to analyses of single
pairs of isolates or isolates that are laboratory derived [11], [12], [13], [14].
To elucidate the genetic factors involved in the evolution of reduced susceptibility to daptomycin in
S. aureus, we performed whole genome sequencing of 33 carefully selected strains, which included
nine clinical isogenic pairs or series (21 strains) and nine laboratory derived mutants from three
parent strains (12 strains). We identified previously described mutations associated with
daptomycin resistance such as mprF, walK and rpoB but most importantly, we identified novel
mutations in two genes responsible for the production of the anionic membrane phospholipids, PG
and cardiolipin. In select clinical pairs, these mutations were associated with changes in
phospholipid membrane composition that would explain a reduced affinity for daptomycin, and
changes in cell wall thickness. This study represents the first large-scale comparative assessment of
genome-wide factors involved in daptomycin-nonsusceptibility in staphylococci derived from active
clinical infections.

M ETHODS
Ethics Statement
The clinical S. aureus isolates used in this study were referred to our laboratory due to persistence
during daptomycin therapy. Ethics approval was not required for this laboratory study, as no patient
identifiers or clinical details apart from the site where the culture was taken (eg blood, bone or

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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heart valve) was obtained. As referenced in Table 1, some of the strains were from previously
published work and some of these publications contain clinical information.

Table 1. Characteristics of the daptomycin
-exposed clinical strains of Staphylococcus
aureus used in this study.
doi:10.1371/journal.pone.0028316.t001

•
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Bacterial strains and culture conditions
Isolates obtained from the same patient were previously confirmed to be isogenic based on pulsedfield gel electrophoresis. All bacteria were stored at −80°C until further testing. Daptomycin
(Cubist, MA) susceptibility testing was performed by broth macrodilution using cation-adjusted
Mueller-Hinton II broth (BD) supplemented to contain a final calcium concentration of 50 µg/ml. To
determine the differences between in vivo and in vitro daptomycin exposure on the genetic
evolution to resistance, three reference S. aureus strains underwent in vitro daptomycin exposure.
A prototype hospital-acquired MRSA strain was selected (MRSA32 [A5948]), as well as an agr+
(RN6607 [A8115]) and its isogenic agr− mutant strain (RN9120 [A8117]). The latter two strains
also enabled an assessment of the effect of agr on daptomycin resistance. In vitro daptomycin
exposure was performed in Brain Heart Infusion (BHI) broth using a high bacterial inoculum (10

8

CFU/ml) and 48 hour exposure to daptomycin at a concentration of 8 µg/ml at 35°C. The culture
was then plated onto agar containing varying concentrations of daptomycin, and single colonies
were chosen for formal susceptibility testing. Three independent mutants from each reference strain
were selected for sequencing. One of the mutants from A5948 was generated previously (A6658)
[15].

Whole genome sequencing
Genomic DNA was extracted according to manufacturer's guidelines (Promega Wizard Genomic Kit).
All daptomycin-susceptible parent genomes were sequenced using 454 FLX pyrosequencing (Roche)
with DNA fragment libraries according to the manufacturer's recommendations. Genomes were
assembled using Newbler and the runAssembly script was then used to assemble reads into contigs.
To remove contaminating sequences, final assemblies were BLASTed to the NCBI non-redundant
(NR) database and UniVecCore. Assembly annotation was performed using a combination of ab
initio and evidence-based approaches. For further details see supplementary material (Text S1). A
summary of gene finding data for each locus can be viewed at the Broad Institute S. aureus Drug
Resistance Project group database
(http://www.broadinstitute.org/annotation/genome/staphylococcus_aureus_drug_resistance/).

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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Single Nucleotide Polymorphism (SNP) and Phylogenetic Analysis
The daptomycin-nonsusceptible daughter strains were sequenced to high coverage (≥100 fold) with
76 nucleotide reads produced on the Illumina platform. The reads were used to call SNPs against
the parent assemblies using the variant ascertainment algorithm (VAAL), a polymorphism discovery
algorithm for short reads developed by the Broad Institute [16]. Select SNPs were confirmed
independently using PCR sequencing. Phylogenetic analysis was performed using single-copy core
gene trees that were generated from orthologous groups computed by orthoMCL
(http://www.orthomcl.org/cgi-bin/OrthoMclWeb.cgi) [17]. An all versus all BLAST was performed
using the predicted protein sequence from all genomes of interest. All BLAST hits with an evalue<1e

−5

were used as input to orthoMCL. To generate trees, nucleotide sequences for all single-

copy core genes were retrieved and aligned by orthologous group [18]. These alignments were
trimmed using trimAL to allow concatenation [19]. Aligned, trimmed and concatenated sequences
were then used to build trees using FastTree [20]. Using the genome sequence for all parent
strains, multi-locus sequence types (MLST) were also determined (http://saureus.mlst.net/). This is
a well established method for determining clonality in S. aureus and utilizes the sequence of seven
house-keeping genes to determine allelic profiles [21]. Predicted transmembrane domains (TMDs)
of proteins were determined using TMHMM v 2.0 [22].

Membrane lipid analysis
Lipid measurements were performed after a modified Bligh and Dyer extraction of the total polar
lipids [23] and quantified using LC-MRM (multiple reaction monitoring) as described in
supplementary material (Text S1). Three independent colonies from each strain were assessed and
each extract was run in triplicate. Differences in the PG:L-PG ratio were assessed by student's t test
at a significance level of P≤0.05.

TEM
Cells were prepared for TEM as described previously [5]. In brief, cells from late-exponential phase
were fixed with 2.5% (vol/vol) glutaraldehyde and 2.0% (wt/vol) osmium tetroxide, and then
stained with 2.0% (wt/vol) uranyl acetate. After embedding in LR White resin and cutting thin
sections, samples were further stained with uranyl acetate and then imaged using a LEO 912AB
microscope. The cell wall of 100 cells for each strain were measured in a blinded fashion and
compared using the student's t test with a significance level of P≤0.05.

R ESULTS AND D ISCUSSION
Clinical and laboratory S. aureus strains exposed to daptomycin
The characteristics of the S. aureus strains used in this study are shown in Tables 1 and 2. All the
clinical pairs or series of S. aureus were obtained from patients with bloodstream infection who
failed or had persistent infection while being treated with daptomycin. Most were complicated by
endocarditis or other deep-seated infection (Table 1). Each pair or series includes the initial
infecting isolate, which was daptomycin-susceptible (MIC≤1 µg/ml), and the subsequent isolate/s
that were daptomycin-nonsusceptible after daptomycin exposure. For most strains, exposure to
daptomycin did not change the MIC to vancomycin (Table 1 and 2). The increase in MIC to
daptomycin for the laboratory exposed strains was equivalent to that seen for the clinical isolates,

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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with no differences observed between agr+ S. aureus (A8115) and its isogenic agr− (A8117)
mutant strain (Table 2). In vitro selection has the advantage of assessing genetic changes specific
to daptomycin exposure alone, but is limited by the absence of host factors and immune responses
that may alter the evolution of daptomycin resistance. This unique collection of carefully selected
isogenic S. aureus strains provided us with an excellent opportunity to investigate the mechanisms
of resistance to one of our last line anti-staphylococcal antibiotics, daptomycin.

Table 2. Characteristics of the daptomycin
-exposed laboratory strains of
Staphylococcus aureus used in this study.
doi:10.1371/journal.pone.0028316.t002
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Whole genome sequencing of daptomycin-susceptible S. aureus parent strains
All daptomycin-susceptible parent genomes were sequenced to an average of 24-fold coverage
(range 14- to 39-fold) and were of similar sizes, ranging from 2.72 Mb to 2.97 Mb (mean of 2.84
Mb). The mean number of putative open reading frames was 2757 (range 2539–3066) and the
percentage GC content was similar between strains (mean 32.72%, range 32.58%–32.84%)
(http://www.broadinstitute.org/annotation/genome/staphylococcus_aureus_drug_resistance/). As
shown in Tables 1 and 2, seven of the parent strains were sequence type (ST) 5 and three were
ST8, which are the more common MLST types in hospital-acquired S. aureus in North America [24].
Two parent strains were ST105, which has been less commonly reported (http://saureus.mlst.net/).
Detailed phylogenetic analysis is shown in Fig. S1, and illustrates the high degree of genetic
conservation between the parent strains isolated from different patients in this study.

Number and type of genetic mutations associated with daptomycin exposure
To investigate the genetic mutations associated with the in vivo or in vitro evolution of daptomycin
resistance, all isogenic daughter strains (21 strains) were sequenced and compared to their
daptomycin-susceptible parent strains. On average, only six coding region mutations were observed
across the entire genome in the clinical in vivo daptomycin exposed strains (range 2–13 mutations),
whereas only two mutations on average (range 1–4 mutations) were seen in the laboratory in vitro
exposed pairs (Table S1). In the clinical pairs, the majority of mutations were SNPs (mean 4, range
2–8), with an average of 2 insertions or deletions per pair. All but three SNPs led to an amino acid
change in their respective proteins (Table S1). Mutated genes were categorized by function to
identify themes of bacterial physiology that may contribute towards reduced susceptibility to
daptomycin (Fig. 1). Interestingly, the most consistent mutation, which was found in all 12 strain
pairs, was a mutation in a gene important for membrane phospholipid biosynthesis, highlighting the
central aspect of cell membrane physiology to susceptibility to daptomycin.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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Figure 1. Percentage of daptomycinexposed pairs (n = 12) with a mutation in
each functional gene category.
All daptomycin-nonsusceptible isolates had at
least one mutation in a gene coding for
phospholipid biosynthesis, including mprF, cls2
or pgsA.
doi:10.1371/journal.pone.0028316.g001

•

Download: PowerPoint slide | larger image (28KB PNG) | original image (144KB TIFF)

Mutations within genes associated with phospholipid biosynthesis
Daptomycin is an anionic molecule but when complexed with calcium ions, its properties and mode
of action are analogous to cationic antimicrobial peptides [9], [25], where interaction with the
negatively-charged cell membrane leads to membrane perturbation and cell lysis [4], [5]. The gene
most frequently mutated in our daptomycin-resistant strains was mprF. Point mutations in this gene
were found in all nine clinical pairs and one laboratory-derived pair (Table 3 and S1). This gene
codes for a large membrane protein that contains 14 transmembrane domains (TMDs), and serves
two key functions; the addition of positively charged lysine residues onto PG to form L-PG, which is
mediated by a C-terminal lysinylation domain, and the translocation of this L-PG to the outer leaflet
of the cytoplasmic membrane, which is mediated by the N-terminal translocation domain [9]. This
acts to neutralize membrane charge and creates resistance to cationic peptides such as host
immune factors and daptomycin, and highlights its importance in bacterial immune evasion and
fitness within the host [9], [26]. It has been previously shown that mprF point mutations in
daptomycin-nonsusceptible isolates are associated with a gain-in-function, leading to greater L-PG
in the outer leaflet of the membrane and a further reduction in the net-negative membrane charge
leading to electrorepulsion [26].

Table 3. Predicted protein changes in clinical- and laboratory-derived daptomycinnonsusceptible isolates of Staphylococcus aureus.
doi:10.1371/journal.pone.0028316.t003
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The predicted amino acid changes associated with the 11 SNPs identified within mprF in this study
are shown in Fig. 2A. All SNPs were independently confirmed by PCR and sequencing. Eight SNPs
were mapped to four positions within the lysinylation and translocation domains (Fig. 2A). One SNP
(G61V) was found within the N-terminal translocation domain only, and two SNPs were mapped to
one position (L826F) in the C-terminal lysinylation domain only (Fig. 2A). We hypothesize that the
latter two predicted amino acid changes may either directly enhance translocation of L-PG to the
bacterial surface by increasing translocase activity of MprF, or enhance lysinylation of PGs leading
to increasing pools of L-PG on the inner leaflet of the membrane [9]. Accumulation of intracellular L
-PG may stimulate translocation to the outer leaflet of the membrane in a gradient-dependent
manner. This would, in turn, exacerbate the reduced net-negative charge of the bacterial surface,
thus contributing to daptomycin non-susceptibility [9], [10], [26]. The importance of mutations
within MprF to daptomycin susceptibility is also shown by the sequence of mutations in the clinical
series (A9781–A9798). As shown in Table 1 and S1, the MIC to daptomycin increased to the

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316

11/15/2012

PLOS ONE: Whole Genome Characterization of the Mechanisms of Daptomycin Resi... Page 8 of 14

nonsusceptible range once the mprF mutation
occurred in A9792 (S295L). Interestingly, the
final isolate of the series (A9798) had a different
mprF mutation (G61V) compared to its
predecessor (A9792), and both strains had
mutations in genes not found in the other. This
suggests that multiple resistant subpopulations
are likely to have been present rather than a
step-wise accumulation in mutations. Finally, not
all daptomycin-nonsusceptible mutants had mprF
mutations, particularly the laboratory-derived
strains, suggesting that host pressures, such as
cationic antimicrobial peptides, may influence
MprF-mediated daptomycin resistance.

Figure 2. Phospholipid biosynthesis genes
are integral to the development of
reduced susceptibility to daptomycin in S.
aureus.
(A) The predicted amino acid changes
associated with the 11 SNPs identified within
mprF. (B) The five mutations identified in cls2
were mapped to four positions in the protein,
all within the two N-terminal transmembrane
domains. (C) Six mutations were identified in
pgsA and were mapped to four positions in the protein, three of which were in transmembrane
domains. The ‘A’ numbers correspond to the daptomycin-nonsusceptible isolates, and the arrows
point to the position of the amino acid change.
doi:10.1371/journal.pone.0028316.g002
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Mutations in a second phospholipid biosynthesis gene were identified in five of the studied pairs
(Tables 3 and S1). This gene was cardiolipin synthase (cls2), mutations of which may have been
predicted to have a role given observations of altered gene expression in a laboratory-derived
daptomycin-nonsusceptible strain [27]. Cardiolipin is an important anionic membrane phospholipid
that is synthesized from the phosphatidyl moiety of two PG molecules by the membrane-bound
enzyme, Cls [28]. Under conditions of stress, such as unfavorable growth conditions or cell-wall
acting antibiotics, cardiolipin can accumulate up to ~25%–30% of membrane phospholipid [28].
Cardiolipin synthase is predicted to contain two TMDs, spanning residues 13–35 and 45–67, as well
as two putative cardiolipin synthase domains across residues 229–256 and 407–434 (Fig. 2B). The
four SNPs identified within Cls2 reside exclusively within the two putative TMDs at the N-terminus of
the protein (Fig. 2B). All mutations were independently confirmed by PCR and sequencing.
Importantly, two of the laboratory-derived daptomycin-nonsusceptible mutants (A10151 and
A10155) from two distinct parent strains (A8115 and A5948; Tables 3 and S1), had only a single
point mutation in cls2, both at the same position and involving the same amino acid change
(Thr33Asn). This single point mutation in cls2 caused an increase in MIC to daptomycin from 0.5

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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µg/ml to ≥2.0 µg/ml in both pairs. No other
gene mutations were identified in these two
pairs based on the whole genome sequence. We
hypothesise that mutations within the TMDs
impair membrane localisation and function of
Cls, resulting in altered cardiolipin synthesis.
These changes alone, or in concert with an mprF
mutation, which was seen in three of the clinical
pairs (Table 3), may be important in the chargebased repulsion of daptomycin, or may alter
binding of daptomycin to the membrane.
Interestingly, it has previously been shown that
cls gene expression, as determined by
microarray analysis, was repressed in a
laboratory-derived daptomycin-nonsusceptible
mutant but mutations in the gene were not
assessed [27]. Finally, adding strength to the
role of cls in daptomycin susceptibility, two
recent reports have described its involvement in
reduced susceptibility to daptomycin in clinical
strains of Enterococcus [29], [30].
A third gene novel to daptomycin susceptibility
and also involved in membrane phospholipid
biosynthesis was also identified, known as CDPdiacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase (pgsA). PgsA is important in the
production of PG, the most abundant anionic membrane phospholipid. Interestingly, mutations in
pgsA have recently been described to be associated with reduced susceptibility to daptomycin in
Bacillus subtilis [31]. Our mutations were only identified in laboratory-exposed strains; however as
shown for cls, a point mutation in pgsA alone (strain A10152) was enough to cause an increase in
MIC of daptomycin from 0.5 µg/ml to 2 µg/ml (Tables 2 and S1). Five SNPs were mapped to three
positions of the protein, and as seen with cls mutations, all these SNPs were within TMDs (Fig. 2C).
One in-frame insertion was also identified (Table 3 and Fig. 2C). Our hypothesis is that these
mutations impair PgsA function leading to reduced PG in the membrane and subsequent surface
charge alterations. Further work is required to characterize the role of this gene in S. aureus
susceptibility to daptomycin. The interaction and significance of mutations in these three
phospholipid biosynthesis genes to daptomycin susceptibility is shown in figure 3.

Figure 3. Schematic of our working hypothesis for the functional effect of the observed
mutations.
mprF mutations lead to an increase in lysinylation of phosphotidylglycerol (PG) to form L-PG, and
an increase in translocation of this positively charged L-PG to the outer leaflet of the membrane,
leading to electrorepulsion of daptomycin. In isolation, or in concert with mprF mutations,
mutations in cls2 may lead to altered membrane charge or effect binding of daptomycin to the
membrane. Finally, PgsA is important in the initial step of phospholipid biosynthesis, converting
CDP-diacylglycerol (CDP-DG) into PG.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028316
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doi:10.1371/journal.pone.0028316.g003
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Host pressure and daptomycin exposure lead to mutations across a functionally diverse
array of genes
We observed a greater number of mutations in our clinical versus laboratory-derived pairs,
highlighting the importance of host immune pressures on the genetic response of S. aureus to an
antimicrobial. Apart from mutations in phospholipid biosynthesis genes, five of the clinical pairs had
at least one mutation in a gene encoding a transcriptional regulator or a two-component signal
transduction system (Fig. 1 and Table S1). These included walK (previously yycG), agr, stp1, tcaR
and rsbU (sigma-B regulation), which are all important cell wall biosynthesis and/or virulence
regulators, with the majority being reported for the first time relating to daptomycin exposure.
Despite mutations in rpoB being initially reported with a laboratory-derived daptomycinnonsusceptible isolate [11], we identified only two pairs (clinical) that had mutations within rpoB
(Table S1). Less common mutations were observed in other systems of physiological function
including carbohydrate and amino acid metabolism, ion and small molecule transporters, and
housekeeping genes (Fig. 1 and Table S1), demonstrating the diverse array of genes mutated
during the in vivo evolution of daptomycin resistance. However, apart from the genes involved in
phospholipid biosynthesis, none of the other genetic mutations were consistently observed across
all the pairs. It is of interest though that several of the mutated genes regulate cell wall
biosynthesis, and have also been implicated in reduced susceptibility to vancomycin [3].
Furthermore, many are associated with virulence regulation, and suggest that these daptomycinnonsuscpetible clinical isolates may have altered virulence; a hypothesis that needs further
evaluation.

Daptomycin induces cell wall thickening and changes in membrane lipid composition
Given the frequency of mutations associated with phospholipid biosynthesis, and the presence of
mutations in genes that regulate cell wall turnover (walK, agr, stp1), we characterized the ratio of
cell membrane lipids (PG:L-PG ratio) and cell wall thickness in two representative clinical pairs
(A8819/A8817 and A8796/A8799). Both these pairs have point mutations in mprF in different
locations of the lysinylation domain (Fig. 2A). Consistent with the described physiology, the
daptomycin-nonsusceptible daughter strain, A8817, had an increase in L-PG in the cell membrane,
with a drop in the PG:L-PG ratio from 3.7 to 1.2 for A8819/A8817 (P<0.05). For the second pair,
despite there being an increase in L-PG in absolute terms (PG:L-PG ratio of 3.2 to 2.5 for
A8796/A8799), the difference was not significant (P = 0.2). It has previously been shown that
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subtle changes in L-PG in the outer membrane leaflet can affect daptomycin susceptibility [9]. In
the same two clinical pairs, we also observed greater cell wall thickness in both daptomycinnonsusceptible isolates versus their susceptible parent strains (Fig. 4), with a mean (±SD)
thickness of 35.7 nm (±4.1) and 42.8 nm (±5.6) in the susceptible strains (A8819 and A8796,
respectively) versus 48.1 nm (±5.9) and 53.2 nm (±7.1) in their corresponding resistant daughter
strains (A8817 and A8799, respectively) (P<0.001 for both). Of note, the genetic mutations in both
these pairs (Table S1) did not clearly explain the increase in cell wall thickness. Other groups have
shown that cell wall thickness in daptomycin-nonsusceptible strains is not a consistent finding [14],
[32], and a more recent analysis suggested that in some strains it may be due to an increase in
wall teichoic acid [33].

Figure 4. Transmission electron
microscopy of two clinical pairs showing a
thickening of the cell wall in the
daptomycin-nonsusceptible isolates.
(A) and (B) represent A8819 (daptomycinsusceptible) and A8817 (daptomycinnonsusceptible), respectively. (C) and (D)
represent A8796 (daptomycin-susceptible) and
A8799 (daptomycin-nonsusceptible),
respectively. P<0.001 for both.
doi:10.1371/journal.pone.0028316.g004
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Conclusions
We have performed whole genome sequencing of the largest collection of daptomycin exposed S.
aureus strains to date. Our data show that mutations in genes responsible for phospholipid
biosynthesis appear important for the development of reduced susceptibility to daptomycin, more
specifically, mutations in mprF, cls2 and pgsA. We hypothesise that mutation in each of these genes
act similarly to reduce the net-negative charge of the cell membrane leading to electrorepulsion of
daptomycin. They may act in isolation or in concert with each other, particularly for mutations in
mprF and cls2 (Fig. 3). Our data also show that in vivo pressures in the setting of daptomycin
exposure select for a range of other genetic mutations, including those involving virulence
regulatory genes. Finally, we have shown in select clinical isolates, the functional significance of the
observed genetic mutations by analysing changes in the cell wall and membrane lipid profiles.
Through use of carefully selected strains and broad-based genomics, this work provides important
insights into the mechanism of resistance to one of our last-line anti-staphylococcal antibiotics,
daptomycin.

S UPPORTING I NFORMATION
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Figure S1.
Phylogenetic analysis of 1230 common single copy genes found in 12 daptomycinsusceptible Staphylococcus aureus parent strains, with Staphylococcus epidermidis ATCC
12228 and RP62A used as outgroups for the analysis.
(PPT)
Table S1.
Mutations identified between daptomycin-susceptible and isogenic daptomycinnonsusceptible strains of Staphylococcus aureus .
(DOC)
Text S1.
More detailed methods.
(DOCX)
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